Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences Inc (NQ: ENVB )

0.3369 -0.0130 (-3.72%)
Streaming Delayed Price Updated: 3:58 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences Inc

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
Via Benzinga
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M. 
Via Benzinga
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today?
Enveric Biosciences stock is up on Tuesday with heavy trading of ENVB shares despite a lack of news from the company this morning. 
Via InvestorPlace
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Broad Range of Patent Issuances
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety and epilepsy. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
From Enveric Biosciences
Via Business Wire
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options. 
Via Benzinga
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
From Enveric Biosciences
Via Business Wire
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being... 
Via Benzinga
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
From Enveric Biosciences
Via Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Is Imunon (IMNN) Stock Up 259% Today?
Imunon stock is up on Tuesday with heavy trading of IMNN shares after posting positive results from a Phase 2 clinical trial. 
Via InvestorPlace
Why Is Ekso Bionics (EKSO) Stock Down 15% Today?
Ekso Bionics stock is down on Tuesday as investors in the company react to its lackluster earnings report for the second quarter of the year. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic as we jump into all of the biggest news that has shares heading higher and lower on Tuesday morning! 
Via InvestorPlace
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Non-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed Orally
Via Benzinga
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
From Enveric Biosciences
Via Business Wire
New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Enveric Biosciences Announces Patent Granted for Drug Candidate
From Enveric Biosciences
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.